CorenBiotech/Merck TROP2 ADC Achieves OS Primary Endpoint in Phase III Gastroesophageal Adenocarcinoma Study

nashnova research
今天发布阅读约 8 分钟

Kelun-Biotech and Merck's TROP2 ADC sac-TMT met its overall survival primary endpoint in the Phase III TroFuse-015 trial, becoming the first drug of its class globally to beat physician's choice in advanced gastric/GEJ adenocarcinoma — clearing the path for regulatory filings.

01

What did this trial actually prove?

Sac-TMT is a TROP2 ADC — an antibody-drug conjugate that delivers a chemo "warhead" directly to cancer cells carrying the TROP2 protein.
The Phase III TroFuse-015 trial enrolled 473 patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who had received two or more prior lines of therapy.
Final analysis showed sac-TMT delivered a statistically significant and clinically meaningful improvement in overall survival (OS) versus treatment of physician's choice (TPC), with consistent results across subgroups regardless of TROP2 expression levels.
This means → it is the first TROP2 ADC anywhere in the world to beat standard options in gastric/GEJ cancer in a Phase III setting — and that dataset is the foundation for regulatory submissions to agencies such as the FDA.
02

Why are the secondary endpoints a mixed bag?

Progression-free survival (PFS) missed — the PFS secondary endpoint, assessed by blinded independent central review (BICR), was not met.
Objective response rate (ORR) favoured sac-TMT numerically, but was not formally tested per the pre-specified analysis plan.
In plain terms = the drug did help patients live longer (OS benefit), but the evidence for slowing tumour progression was weaker — regulators may press on this gap.
No new safety signals emerged; the profile was consistent with prior sac-TMT studies.
03

What does this mean for the Kelun-Biotech / Merck partnership?

TroFuse-015 is the second positive Phase III readout from the TroFuse programme, which currently has 18 global Phase III trials running across endometrial, bladder, breast, cervical, gastric, NSCLC, and ovarian cancers.
14 of those 18 are exploring first-in-class opportunities — this reflects Merck's positioning of sac-TMT as a broad oncology platform, not a single-indication asset.
Sac-TMT was licensed to Merck (ex-Greater China) by Kelun-Biotech in May 2022, with an upfront payment plus milestones capped at $1.363 billion and tiered royalties on net sales.
Across the full ADC collaboration since May 2022, combined upfront and milestone payments could exceed $11.8 billion.
04

Where does the drug stand in China?

Sac-TMT (brand name Jiatailai® / 佳泰莱®) is already approved in China for four indications: triple-negative breast cancer, EGFR-mutant NSCLC, and HR+/HER2− breast cancer.
It has also received six Breakthrough Therapy designations from China's NMPA.
This means → whether TroFuse-015's positive readout can accelerate global regulatory timelines for the gastric/GEJ indication is the next critical milestone — full data will be presented at an upcoming medical conference.

市场有风险,内容仅供研究参考,不构成投资建议。